Pipeline

With deep insight into Melanoma and Merkel Cell Carcinoma, we develop curative treatments for patients with no available treatment today.

Metastatic Melanoma       Poke-101

Metastatic Melanoma is the most common type of skin cancer and the type of cancer that best responds to immunotherapy. Despite this, the outlook for Metastatic Melanoma is poor and new treatment options are needed. T cell therapy with Tumor Infiltrating Lymphocytes is known to generate good results in clinical testing. PokeAcell aims to provide best-in-class T cell therapy to treat patients without resectable tumor lesions.

Poke-101 is a shared antigen responding T cell product created from PokeAcell’s ImmPACT activation technology, based on 30 carefully selected Melanoma antigens. Poke-101 is currently in preclinical testing and is in preparation for phase I clinical evaluation in an investigator lead clinical trial at the Center for Cancer Immune Therapy at Herlev Hospital in Denmark.

Merkel Cell Carcinoma   Poke-102

Merkel Cell Carcinoma is a virus-induced rare form of skin cancer with 5000-6000 patients diagnosed annually. Merkel Cell Carcinoma patients generally respond well to checkpoint inhibition, but more than 60% of patients will still need follow-up therapy, of which none exist today. Merkel Cell Carcinoma patients who do not respond to checkpoint inhibitors lack a sufficient T cell response. We aim to provide a T cell response in the form of our ImmPACT T cell product.

Poke-102 is a virus antigen responding T cell product created from the PokeAcell ImmPACT activation technology with selected Merkel Cell Carcinoma virus antigens. Poke-102 is currently in pre-clinical development and will move towards clinical testing based on the initial outcome of poke-101.

Next generation antigens and ImmPACT T cell products

Multiple cancers can be addressed pending detailed insight into the antigen landscape. PokeAcell has distinct capabilities in antigen identification and selection, including Neoantigen selection. We are working on developing the next generation ImmPACT cell product targeting other cancer indications with large unmet needs.